Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 9:14:1432310.
doi: 10.3389/fonc.2024.1432310. eCollection 2024.

Survival outcomes of patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation in Germany: real-world evidence from an administrative database between 2010 and 2019

Jan-Michel Heger  1 , Peter Borchmann  1 , Sybille Riou  2 , Barbara Werner  3 , Michael S Papadimitrious  2 , Jörg Mahlich  2   4
Affiliations

Survival outcomes of patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation in Germany: real-world evidence from an administrative database between 2010 and 2019

Jan-Michel Heger et al. Front Oncol. .

Abstract

Background: Limited real-world evidence is available for patients with diffuse large B-cell lymphoma (DLBCL) who received an autologous stem cell transplantation (ASCT) in Germany.

Objectives: This study aims to describe the real-world survival outcomes of patients with DLBCL who received ASCT in Germany after diagnosis.

Design: This study is a retrospective database analysis covering the period between 2010 and 2019.

Methods: Unadjusted overall survival (OS) was plotted using the Kaplan-Meier estimator for the overall population and stratified by relapse status. A Cox regression was run to identify factors that influence OS.

Results: A total of 112 patients received an ASCT, with the average time from first-line treatment to ASCT being 11.7 months. The median OS estimated by Kaplan-Meier was 83.4 months for the entire cohort. The only variable that significantly reduced the OS was the presence of subsequent treatment after ASCT in a time-dependent model.

Conclusion: OS after ASCT for DLBCL patients in Germany is higher than previously reported and may still be considered a valid option for carefully selected patients with relapsed/refractory DLBCL.

Keywords: Germany; autologous stem cell transplantation; claims data; diffuse large B-cell lymphoma; real-world evidence; survival.

PubMed Disclaimer

Conflict of interest statement

JM, SR, and MP are employees of Miltenyi Biomedicine GmbH. BW is an employee of Team Gesundheit, a contract research company that received funding from Miltenyi Biomedicine to conduct the study in line with the study protocol. The authors declare that this study received funding from Miltenyi Biomedicine. The funder had the following involvement in the study: three authors received salaries from Miltenyi Biomedicine. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier curves for the survival times in months after ASCT. (A) Kaplan–Meier curve for the survival time in months from the first ASCT, overall cohort. (B) Kaplan–Meier curve for the survival time in months from first ASCT, stratified by subsequent therapy after ASCT. (C) Kaplan–Meier curves for the survival times in months from first ASCT onward, stratified by early/late relapse after first-line therapy. (D) Kaplan–Meier curves for the survival times in months from the first ASCT onward, stratified by early/late relapse after ASCT.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Shadman M, Pasquini MC, Ahn KW, Chen Y, Turtle CJ, Hematti P, et al. . Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. (2022) 139:1330–9. doi: 10.1182/blood.2021013289 - DOI - PMC - PubMed
    1. Kamdar MK, Solomon S, Arnason J, Johnston PB, Glass B, Bachanova V, et al. . Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study. JCO. (2024) 42:7013–3. doi: 10.1200/JCO.2024.42.16_suppl.7013 - DOI
    1. Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, et al. . Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. (2023) 389:148–57. doi: 10.1056/NEJMoa2301665 - DOI - PubMed
    1. Tun A, Maliske S, Wang Y, Inwards DJ, Habermann TM, Micallef I, et al. . Progression-free survival at 24 months as A landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma. Transplant Cell Ther. (2022) 28:610–7. doi: 10.1016/j.jtct.2022.06.015 - DOI - PubMed
    1. Wullenkord R, Berning P, Niemann AL, Wethmar K, Bergmann S, Lutz M, et al. . The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis. Ann Hematol. (2021) 100:2733–44. doi: 10.1007/s00277-021-04650-5 - DOI - PMC - PubMed

LinkOut - more resources